Octant is pioneering a new approach to drug discovery by focusing on the cellular mechanisms that underlie various diseases, particularly those related to protein misfolding and mistrafficking. The company employs advanced techniques in synthetic biology and chemistry to develop next-generation small molecule therapeutics. Their platform, known as the Octant Navigator, utilizes high-throughput synthetic biology to create custom sensors within human cells. This allows for the modeling and understanding of complex cellular interactions and the effects of drug candidates on cellular functions. By leveraging barcoded multiplexing, Octant can conduct massively parallel drug discovery, quantifying subtle effects across thousands of experiments, which is essential for advancing their drug programs.

In addition to their synthetic biology efforts, Octant integrates Generative Biology and Generative Chemistry to enhance their drug discovery process. This involves the use of advanced machine learning and automation technologies to iterate rapidly on drug design, enabling the screening of large libraries of related molecules. Their approach includes Deep Mutational Scanning (DMS), which allows for the exploration of protein function by creating uniquely barcoded cell lines for every amino acid variant. This comprehensive methodology not only aims to develop effective therapies for diseases like retinitis pigmentosa but also seeks to address a broader range of conditions by targeting multiple mutations simultaneously, thereby maximizing patient coverage and therapeutic potential.

United States

Octant is a well-backed team of experienced scientists and entrepreneurs exploring new frontiers of biology. We are applying next-generation DNA sequencing, gene synthesis, and gene editing to revolutionize drug discovery in a quest for safer, more effective, and cheaper drugs.

Octant

Company Details